cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Abbvie Inc
340 own
156 watching
Current Price
$136.87
$3.43
(2.57%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
241,434.44M
52-Week High
52-Week High
168.11
52-Week Low
52-Week Low
131.1
Average Volume
Average Volume
6.66M
Dividend Yield
Dividend Yield
0.044376
P/E Ratio
P/E Ratio
27.6386
iconMarket Capitalization241,434.44M
icon52-Week High168.11
icon52-Week Low131.1
iconAverage Volume6.66M
iconDividend Yield0.044376
iconP/E Ratio27.6386
What does the Abbvie Inc do?
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; and M2Gen. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Read More
How much money does Abbvie Inc make?
News & Events about Abbvie Inc.
Fool.com Headlines
1month ago
Vertex dominates the cystic fibrosis market today.Vertex Pharmaceuticals (NASDAQ: VRTX) is the global leader in cystic fibrosis (CF) treatment. The company is known for its combination therapies targeting a defective protein that causes the disease's devastating symptoms.But one possible threat to ...
Fool.com Headlines
1month ago
You'll want to hold on to these top stocks for the long term.If you have $20,000 to invest, you could put it all in one stock -- or you could invest across several. I favor buying a few stocks that can each offer you something different. For instance, one may pay you a top-notch dividend, another ...
PR Newswire
1month ago
AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant...
PR Newswire
1month ago
Allergan Aesthetics Celebrates the Journeys of Women Surgeons with LIMITLESS Allergan Aesthetics Celebrates the Journeys of Women Surgeons with LIMITLESS PR Newswire IRVINE, Calif., April 18, 2023 Women surgeons breaking the boundaries of leadership presented in partnership with the American...
PR Newswire
1month ago
AbbVie Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease AbbVie Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease PR Newswire NORTH...
Frequently Asked Questions
Frequently Asked Questions
What is Abbvie Inc share price today?
plus_minus_icon
Can Indians buy Abbvie Inc shares?
plus_minus_icon
How can I buy Abbvie Inc shares from India?
plus_minus_icon
Can Fractional shares of Abbvie Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Abbvie Inc stocks?
plus_minus_icon
What is today’s traded volume of Abbvie Inc?
plus_minus_icon
What is today’s market capitalisation of Abbvie Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Abbvie Inc?
plus_minus_icon
What percentage is Abbvie Inc down from its 52-Week High?
plus_minus_icon
What percentage is Abbvie Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$136.87
$3.43
(2.57%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Novartis AG
Novartis AG
$98.91
$1.80 (1.85 %)
Merck & Co. Inc.
Merck & Co. Inc.
$112.52
$1.59 (1.43 %)
Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co.
$65.66
$0.98 (1.52 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$333.78
$10.16 (3.14 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Novartis AG
Novartis AG
$98.91
$1.80 (1.85 %)
Merck & Co. Inc.
Merck & Co. Inc.
$112.52
$1.59 (1.43 %)
Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co.
$65.66
$0.98 (1.52 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$333.78
$10.16 (3.14 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00